International Myeloma Working Group recommendations for global myeloma care

H. Ludwig*, J. S. Miguel, M. A. Dimopoulos, A. Palumbo, R. Garcia Sanz, R. Powles, S. Lentzsch, W. Ming Chen, J. Hou, A. Jurczyszyn, K. Romeril, R. Hajek, E. Terpos, K. Shimizu, D. Joshua, V. Hungria, A. Rodriguez Morales, D. Ben-Yehuda, P. Sondergeld, E. ZamagniB. Durie

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

156 Scopus citations


Recent developments have led to remarkable improvements in the assessment and treatment of patients with multiple myeloma (MM). New technologies have become available to precisely evaluate the biology and extent of the disease, including information about cytogenetics and genetic abnormalities, extramedullary manifestations and minimal residual disease. New, more effective drugs have been introduced into clinical practice, which enable clinicians to significantly improve the outcome of patients but also pose new challenges for the prevention and management of their specific side effects. Given these various new options and challenges, it is important to identify the minimal requirements for diagnosis and treatment of patients, as access to the most sophisticated advances may vary depending on local circumstances. Here, we propose the minimal requirements and possible options for diagnosis, monitoring and treatment of patients with multiple myeloma.

Original languageAmerican English
Pages (from-to)981-992
Number of pages12
Issue number5
StatePublished - May 2014
Externally publishedYes

Bibliographical note

Funding Information:
We wish to acknowledg the secretarial assistance of Raphaela Oswald and the support by the International Myeloma Foundation and Austrian Forum against Cancer.


  • global perspective
  • management of myeloma-related side effects
  • myeloma care


Dive into the research topics of 'International Myeloma Working Group recommendations for global myeloma care'. Together they form a unique fingerprint.

Cite this